Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.

J Prev Alzheimers Dis · 2026 · PMC13098421 · PMID 42000569

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The differences on change in ADAS-cog 13 and WBV between the HMTM 16 mg/day group and the matched placebo group were highly significant at 78 weeks, and also at 52 (ADAS-cog 13 only) and 104 weeks.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.